Photosensitivity Risk Assessment
Neither tamsulosin (FLOMAX) nor rosuvastatin (CRESTOR) are listed as photosensitizing medications in the FDA drug labels, and neither drug appears in guideline-based lists of medications commonly associated with drug-induced photosensitivity.
Tamsulosin (FLOMAX) 0.4 mg
The FDA drug label for tamsulosin does not list photosensitivity as an adverse reaction 1. The most common adverse events reported include:
- Abnormal ejaculation (8.4-18.1%)
- Dizziness (14.9-17.1%)
- Rhinitis (13.1-17.9%)
- Headache (19.3-21.1%)
No photosensitivity reactions were documented in clinical trials or postmarketing surveillance 1. Recent safety data from 2026 confirms tamsulosin demonstrates no adverse effects on metabolic parameters when used alone or in combination therapy 2.
Rosuvastatin (CRESTOR) 5 mg
The FDA drug label for rosuvastatin does not list photosensitivity as a contraindication or adverse reaction 3. However, the evidence regarding rosuvastatin and photosensitivity is more nuanced:
Evidence for Potential Photosensitivity:
Statins, including rosuvastatin, appear in a 2022 guideline listing medications linked to drug-induced photosensitivity 4. Specifically, HMG-CoA reductase inhibitors (atorvastatin, pravastatin, and simvastatin) are mentioned, though rosuvastatin is not explicitly named in this list 4.
Research evidence suggests:
- Rosuvastatin's photoproduct (ppRSV) demonstrates photosensitizing properties in laboratory studies, with potential to cause DNA damage and oxidative stress 5
- A 2022 case report documented photolocalized purpura induced by rosuvastatin 6
- A 2025 FAERS database analysis did not identify rosuvastatin as a signal drug for photosensitivity 7
Clinical Significance:
The actual clinical risk appears extremely low. While laboratory studies show theoretical photosensitizing potential through rosuvastatin's photoproduct, this represents a rare idiosyncratic reaction rather than a common adverse effect. The 2022 guideline's inclusion of statins in photosensitivity lists focuses primarily on other statins (atorvastatin, pravastatin, simvastatin) 4.
Clinical Recommendations
For practical purposes, neither medication requires routine sun protection counseling beyond standard recommendations. However:
- If your patient develops unexplained skin reactions in sun-exposed areas while taking rosuvastatin, consider photosensitivity as a rare differential diagnosis
- No special precautions are needed for tamsulosin regarding sun exposure
- Standard sun protection (SPF 30+ sunscreen, protective clothing, avoiding midday sun) remains appropriate for all patients but is not specifically indicated due to these medications 4
The risk-benefit analysis strongly favors continuing these medications without photosensitivity concerns, as both drugs provide significant cardiovascular and urological benefits with well-established safety profiles.